The Development of Lifitegrast to Treat Dry Eye Syndrome • iBiology
Mechanism of Action | Xiidra® (lifitegrast ophthalmic solution) 5%
NDA 208073/S-005 Page 3
An Engineered Contact Lens for Passive and Sustained Release of Lifitegrast, an Anti-Dry Eye Syndrome Drug | bioRxiv
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease - ScienceDirect
LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease | Journal of Ocular Pharmacology and Therapeutics
Ophthalmology Management - SIMPLIFYING THE COMPLICATED: OCULAR SURFACE DISEASE AND THE KISS PRINCIPLE
Deeper Insight THERAPY 5 - ANTI-INFLAMMATORY Therapy — Ocular Surface Center Berlin
LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease
Untitled
Lifitegrast ophthalmic solution in the treatment of signs and symptoms | OPTH
Form 10-K
Mechanism of action (MOA) of lifitegrast at the cellular level. ICAM-1... | Download Scientific Diagram
File:EMA401 Mechanism of Action.jpg - Wikimedia Commons
CRSToday | Dry Eye Disease: Integrating Old and New Therapies
A Review of Topical Cyclosporine A Formulations—A Disease-Modify | OPTH
Current understanding of the mechanism of action of lifitegrast in DED.... | Download Scientific Diagram
Ophthalmology Management - SIMPLIFYING THE COMPLICATED: OCULAR SURFACE DISEASE AND THE KISS PRINCIPLE
lifitegrast | 1025967-78-5
